Stay updated on Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedPublication notes were adjusted to specify that PubMed-listed publications are auto-generated and may not be related to the study. The revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check28 days agoChange DetectedThe notice about lapse in government funding and NIH operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedThe update involves formatting and layout adjustments to the study details page and does not modify core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference2%

- Check78 days agoChange DetectedUpdate includes adding revision v3.1.0 and removing the Melanoma/Cutaneous Malignant category, replacing the older v3.0.2 marker.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion bumped to v3.0.2 and Back to Top removed; overall, no significant changes to core content or critical data.SummaryDifference0.1%

Stay in the know with updates to Aldesleukin and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aldesleukin and Pembrolizumab in Melanoma Clinical Trial page.